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Today, we are facing a major challenge regarding the development of new strategies 
and the discovery of new compounds with effective antimicrobial outcomes. The 
emergence of resistance is a preoccupant health threat and conventional antibiotics 
are being rendered ineffective. Researchers are now focusing in alternatives, such as 
the discovery of new antimicrobials with different modes of action, and the 
combination of agents potentiating their efficacy. AMPs are an example of new 
antimicrobials with promising applications, since they have different and sometimes 
unspecific mechanisms of action compared to traditional antibiotics, reducing the 
chance of acquired resistance. 
This work analyses AMP combinations against major pathogenic bacteria, 
Pseudomonas aeruginosa and Staphylococcus aureus, currently great contributors for 
resistance development and responsible for chronic infections, such as cystic fibrosis 
pneumonia. We present a screening of combinations of colistin with temporin A, 
citropin 1.1, tachyplesin I, lactoferricin B, magainin II and GlOKHc, against these 
pathogens, including references and clinical isolate strains. Results show that most 
combinations have synergetic activities, which means that AMP combinations should 
be a viable way for the development of new antimicrobial treatments, thus reducing 
their toxicity and side effects, while maintaining efficacy. 
Some of the best combinations will be tested on biofilms of these bacteria, in order 
to test their prophylactic and therapeutic action against this different and more 
resilient mode of growth. 
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